Eversheds Sutherland advises Azurity Pharmaceuticals on Acquisition of Sebela’s Bowel Prep Franchise

The strategic transaction further strengthens Azurity’s commitment to serving overlooked patients by advancing access to medicines. By integrating Sebela’s bowel prep franchise, Azurity will expand its product offerings and capabilities to healthcare providers and patients in the United States.

With the acquisition, Azurity welcomes more than 50 colleagues from Sebela’s commercial and support teams.

Read Azurity’s press release here.

The Eversheds Sutherland team was led by Partner Mike Voynich (Corporate), with support from Partner Pete Pappas (Intellectual Property), Special Counsel Anna Halsey (Intellectual Property), Senior Associate Adam Byrne (Corporate) and Associate Haley Klass (Corporate).